ProCE Banner Activity

Targeting the MDM2-p53 Pathway in Biliary Tract Cancer: Emerging Data and Implications for Future Clinical Practice

Slideset

Downloadable slideset on the current guidelines and recommendations for molecular testing in advanced BTC, rationale for targeting MDM2/p53 signaling in BTC, and potential future role of MDM2 inhibitors in BTC from Patricia LoRusso, DO, PhD(h).

Released: August 29, 2024

Expiration: August 28, 2025

Share

Faculty

Patricia LoRusso

Patricia LoRusso, DO, PhD(h)

Associate Center Director, Experimental Therapeutics
Director, Early Phase Clinical Trials Program
Yale Cancer Center
Yale University
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.